Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Biotech Stock Gainers for Monday: (OTCBB: UVFT), (NASDAQ:BPAX), (OTCBB: ACTC), (NASDAQ:OXGN)

Biotech Stock Gainers for Monday: (OTCBB: UVFT), (NASDAQ:BPAX), (OTCBB: ACTC), (NASDAQ:OXGN)
(OTCBB: UVFT) Trades High Volume on News
Point Roberts, WA – November 29, 2010 ( Newswire) -, a leader in sector research for investors including biotech stocks , reports on recent  volume leading Biotech/ Pharma stocks news and trading for November 29th on the OTCBB and NASDAQ Markets.
Biotech Stocks featured in this trading alert include UV Flu Technologies, Inc., (OTCBB: UVFT), Oxigene Inc. (NASDAQ: OXGN), BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), andAdvanced Cell Technology Inc. (OTCBB: ACTC)
Biotech Sector Snapshot: (Trading at time or release)
UV Flu Technologies, Inc.,(OTCBB: UVFT), trading at $ 0.22, up 0.03 (15.79%) on over 700,000 shares in Volume
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) trading at $1.46, up 0.06 (4.29%)
Oxigene Inc. (NASDAQ: OXGN) trading at $0.2126, up 0.0022 (1.05%)
Advanced Cell Technology Inc. (OTCBB: ACTC) trading at $0.0767, up 0.0037 (5.04%) on over 6 Million shares in Volume
Biotech Stocks News Hi-lights  
UV Flu Technologies Highlights 2010 Operations as ViraTech UV-400 is Selected as Product of Choice by National Clean Air Foundation
CENTERVILLE, MA – November 29, 2010 ( Newswire) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company"), manufacturers of innovative air purification technology announced today that the Company has been informed by one of its distributors, INE Global, of Boston, Mass, that “Clean Air for Everyone,” a national non-profit promoting clean air for schools and non-profits around the Country has selected the ViraTech UV-400 as the lead product to be distributed throughout America.
“This product can help our schools, and the children within them,” said John Pappas, spokesperson for ‘Clean Air for Everyone.’ “There are thousands of schools, homeless shelters, and Aids clinics around the country, that suffer through horrific air quality, due to the lack of funding to correct or improve the situation. The UV-400 kills the bacteria, odors, VOCs, and other organic contaminants that cause sickness, respiratory problems, and allergies that make our children ill.”
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) Recent News:
Biotech/Pharma Stock News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) Sells Oncolytic Virus Technology to Cold Genesys, Inc.
LINCOLNSHIRE, Ill. - November 17, 2010 ( newswire) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.
 Oncolytic (cancer cell killing) virus therapy is novel therapy that utilizes adenoviruses, a cause of the common cold, which are engineered to selectively replicate in targeted cancer cells, thereby killing these cells while leaving healthy cells largely unharmed. The virus is designed to replicate in cancer cells producing large amounts of oncolytic virus until the cancer cell can no longer contain the virus and bursts. The tumor cell is destroyed and the newly created oncolytic virus spreads to neighboring cancer cells to continue the cycle of viral replication and tumor cell destruction.
Stephen M. Simes, president and CEO of BioSante, said, "This is an important step in maximizing the value of technologies acquired late last year. This transaction allows us to transfer our oncolytic virus technology to a company with the expertise and ability to move it along the development path. By maintaining an ownership position in Cold Genesys, Inc. as well as the potential for future milestone and royalty payments, we have maintained important 'upside' in this exciting technology."
Advanced Cell Technology Inc. (OTCBB: ACTC) Recent News:
Advanced Cell Technology Receives FDA Clearance for the First Clinical Trial Using Embryonic Stem Cells to Treat Macular Degeneration
“Advanced Cell Technology, Inc. announced today that the US Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (NYSE:IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem cells (hESCs) to treat patients with Stargardt’s Macular Dystrophy (SMD), one of the most common forms of juvenile macular degeneration in the world. The decision removes the clinical hold that the FDA had placed on the trial.
Stargardt’s Macular Dystrophy causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium (RPE). . “There is currently no treatment for Stargardt’s disease,” said Dr. Robert Lanza, ACT’s Chief Scientific Officer. “Using stem cells, we can generate a virtually unlimited supply of healthy RPE cells, which are the first cells to die off in SMD and other forms of macular degeneration. We’ve tested these cells in animal models of eye disease. In rats, we’ve seen 100% improvement in visual performance over untreated animals without any adverse effects. Our studies showed that the cells were capable of extensive rescue of photoreceptors in animals that otherwise would have gone blind. Near-normal function was also achieved in a mouse model of Stargardt’s disease. We hope to see a similar benefit in patients with various forms of macular degeneration.”
About is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including mining and gold stocks, in addition to global markets including China, India, the Middle East and Australia. is known for its comprehensive stock directories in each sector and sector specific newswires.
Research more biotech stocks at the Biotech stocks Directory:
About our Biotech investor portal: Portal is a global meeting place for investors and industry following the sector, within Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.
Visit the showcase page on For UV Flu Technologies, Inc.,(OTCBB: UVFT)
Visit the BPAX showcase profile at
Get added to the company’s news alerts:
Disclaimer: Disclaimer: The following news/content is paid for as part of the BPAX and UVFT showcase programs (three thousand per month each) is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclaimer:
C Van Zant: 800-665-0411 -
Source -

Disclosure: Disclaimer: Disclaimer: The following news/content is paid for as part of the BPAX and UVFT showcase programs (three thousand per month each)